Imaging Biomarkers to Support a Differential Diagnosis: What is Underlying?
Philip Scheltens, MD, PhD, discusses the use and results of imaging and fluid biomarkers in the patient case study. Marwan Sabbagh, MD, then describes the value and use of biomarkers in the diagnosis of Alzheimer’s disease (including imaging and CSF biomarkers), particularly for differential diagnosis across dementia etiologies.
Key Learning Objectives for Biogen’s AAIC 2018 Symposium:
- Understand the importance and challenges of an early diagnosis of Alzheimer’s disease
- Broaden understanding of the use of neuropsychological tools and imaging and fluid biomarkers to leverage an earlier diagnosis of Alzheimer’s disease
- Highlight the value of biomarkers for assessing differential diagnosis across dementia etiologies
- Explore clinical management options for patients with a diagnosis of Alzheimer’s disease in the early stages, including current non-pharmacological interventions
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.